Are children with severe community-acquired pneumonia more likely to have Mycoplasma pneumoniae?
Community-acquired pneumonia (CAP) is a common lung infection in children. Mycoplasma pneumoniae is a frequent cause, and research suggests it may be more common in severe cases. Two recent studies found that children with severe CAP had higher rates of Mycoplasma pneumoniae infection compared to those with milder illness. This information can help guide testing and treatment decisions.
What the research says
A 2025 study using targeted next-generation sequencing (tNGS) in 1845 children with CAP found that Mycoplasma pneumoniae was detected in 35.8% of those with severe CAP, compared to only 8.9% in non-severe CAP 6. This difference was statistically significant, meaning it is unlikely to be due to chance. Another study from 2024 on children hospitalized with human metapneumovirus (HMPV) infection also found that co-infection with Mycoplasma pneumoniae was an independent risk factor for severe CAP 2. Together, these findings indicate that Mycoplasma pneumoniae is more common in children with severe pneumonia. Additionally, macrolide resistance is very high in some regions: a 2024 study in China found that 94.4% of Mycoplasma pneumoniae isolates from children with CAP were resistant to macrolide antibiotics like azithromycin 4. This resistance may make treatment more challenging and could contribute to more severe illness.
What to ask your doctor
- Should my child be tested for Mycoplasma pneumoniae if they have severe pneumonia?
- What is the local rate of macrolide resistance for Mycoplasma pneumoniae, and how does that affect treatment choices?
- Are there other viruses or bacteria that commonly co-infect with Mycoplasma pneumoniae and worsen severity?
- What signs should I watch for that might indicate the infection is becoming severe?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.